ABSTRACT

During HIV infection, hematological manifestations are frequently associated with various pathogenic mechanisms, which require a multidisciplinary approach. We present the case of a 57-year-old patient with pancytopenia associated with Kaposi’s sarcoma, as indicative manifestations of the acquired immunodeficiency syndrome. The late diagnosis of HIV infection, in the stage of severe immunosuppression, the association of opportunistic neoplasia, delayed oncological therapy and the development of immune reconstruction syndrome after starting antiretroviral therapy have contributed to the severe evolution and death of the patient.

Keywords: HIV infection, pancytopenia, Kaposi’s sarcoma, IRIS

INTRODUCTION

Pancytopenia is a syndrome often found in hematological clinical practice, defined by the concomitant decrease of the three hematopoietic lines, characterized by hemoglobin values < 10 g/dl, leukocytes < 4,000/mm3 and platelets < 150,000/mm3 (1).

Pancytopenia is not a disease by itself, but can suggest the first sign of several pathologies, with various etiologies, which are classified into the following groups: decreased bone marrow function (spinal cord aplasia, spinal cord infiltration), inefficient erythropoiesis (megaloblastic anemia) or increased peripheral destruction (2). Human immunodeficiency virus (HIV) infection is often associated with pancytopenia, which can occur through multiple mechanisms, especially induced by the direct cytopathic effect of HIV, opportunistic infections, immune mechanisms, neoplasms, drug toxicity (3). Frequency and severity of HIV-associated hematological manifestations are higher in advanced stages of immunosuppression (AIDS), characterized by high viral replication and low levels of T-CD4 lymphocytes. Chronic inflammatory response, accompanied by the release of cytokines that can change all lines of hematopoiesis and increase cytopenia by immune mechanisms (4).

Hematological disorders can be inaugural to the diagnosis of HIV, even in the absence of clinical symptoms.

CASE PRESENTATION

We present the case of a 57-year-old patient, retired, from urban areas, who presented to the hematology service for the suspicion of a lymphoproliferative syndrome, in the context of lymphadenopathy, accompanied by fever and weight loss ~ 10% of body weight, with a progressive evolution in the last 3 months. The late presentation to the doctor was motivated by the pandemic...
context of COVID-19 and the fear of contacting the disease. The medical history mentions a natural birth, two abortions, duodenal ulcer, osteoporosis, tachyarrhythmia and a persistent biological syndrome of 3 years, apparently unexplained. She denies smoking, drinking alcohol or recreational substances and has been living alone for over 10 years, being divorced.

The clinical exam revealed: moderately influenced general condition, conscious, with depressive mood, afebrile, BP = 130/80 mmHg, HR = 100 bpm, FR = 16 breaths/min, SO2 = 97% in the ambient air; bilateral enlargement of the lymph nodes, of 2-3 cm diameter, hard consistency, fixed to the underlying tissues, located submandibular, laterocervical, supraclavicular, axillary and inguinal; slightly infiltrated read-purple skin lesions, with dimensions between 1 and 3 cm, located at the left oral commissure, upper chest, right breast and submammary region; tonsillar hypertrophy, diffuse purplish erythema on the hard palate with infiltrative appearance, dentures and candidiasis were found on the oral examination (see figure 1).

Laboratory tests revealed pancytopenia, severe inflammatory syndrome, hypoalbuminemia (Table 1). Tumor markers CA19.9, CA125, CA15.3, ACE were within safe limits. The medullogram exam, with discrete growth of plasma cells, slight suppression on the erythrocyte and granulocyte lines, usually implies a persistent inflammatory syndrome.

Contrast-enhanced cervico-thoraco-abdominopelvic CT-scan confirms clinically described peripheral lymphadenopathy, the association of mediastinal and retroperitoneal lymphadenopathy, and the presence of a 25 mm liquid blade in the pouch of Douglas.

The macroscopic appearance of the skin lesions was suggestive of Kaposi’s sarcoma, that is frequently related to severe immunosuppression human immunodeficiency virus (HIV). The infection was confirmed by ELISA and Western Blot tests. The biopsy of the right supraclavicular lymph node was performed. The histopathological findings, correlated with immunohistochemical tests, were matching with Kaposi’s sarcoma of the lymph node, HHV-8 positive in vascular proliferation (Table 1).

The first specific evaluation for HIV infection indicates high viral replication, with HIV-RNA = 368,000 copies/ml and severe immunosuppression of LT-CD4 = 42/mmc, classifying as C3 stage, according to CDC (5,6). Markers for HBV, HCV, lues were negative. She received antifungal treatment for Candidiasis (Fluconazole), prophylaxis of pneumocystosis and atypical mycobacteria (Cotrimoxazole, Clarithromycin) and antiretroviral treatment with Genvoya (Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide). The hematological evolution seemed favorable after 6 weeks, due to the improvement of the count blood cells, the increase of L-CD4 to 192/mmc, along with the significant decrease of the viral replication. However, the general condition was worsening, with fever, extensive skin and oral mucosal lesions, difficulty in swallowing and breathing. This paradoxical evolution fits within the definition of inflammatory immune reconstruction syndrome (IRIS), with clinical outcome improved after corticosteroid therapy, in the next 2 weeks. The serial CT imaging revealed the bilateral extension of the enlarged lymph nodes, in the upper and middle abdomen, retroperitoneal, iliac, mediastinal and cardio-phrenic, and the appearance of right pleurisy and iodophilic infiltrates in the soft parts of the epicranial, cervical, parotid, mouth and hypopharynx. Examination of pleural fluid and pneumology evaluation ruled out tuberculosis. Further, febrile episodes reappeared, with predominantly nocturnal sweating, weight loss and progressive clinical decline, dying after 16th weeks from HIV diagnosis.

**DISCUSSION**

Kaposi’s sarcoma (KS) is an angioproliferative tumor, derived from endothelial cells, with multifactorial etiology, associated with human herpesvirus 8 (HHV-8) infection (7). Depending on the circumstances in which KS is expressed, there are
recognized four subtypes: classic, occurring in the elderly; endemic, described in indigenous Africans in the sub-Saharan region, iatrogenic, developed after immunosuppressive therapy, especially after kidney transplantation, epidemic, associated with acquired immunodeficiency syndrome (AIDS) (8,9).

Epidemic KS is the most common AIDS-related cancer that occurs in the United States (6). Although KS was more than 20,000 times more common in people with AIDS than the general population, the incidence has dropped significantly after highly active antiretroviral therapy (ART) become largely accessible. Nowadays, KS is rare reported but with high mortality (10,11). The KS frequency is 2-3 times higher in men than in women (12). The spectrum of clinical manifestations includes: forms limited to red-purple or brown skin lesions, oral mucosal lesions, lymphadenopathy, lymphedema and / or visceral lesions with various locations, especially pulmonary and gastrointestinal (10-12).

A particular situation for KS in patients with severe acquired immunosuppression is the development of inflammatory reconstruction immune syndrome (IRIS) after the initiation of ART, in the first weeks after the start of therapy (13). This syndrome is characterized by a paradoxical inflammatory response, as a result of decreased viral load and restoration of L-CD4 immunity, manifested in the first 3 months after initiating ART, by exposing a latent infection or by aggravating the symptoms of an opportunistic infection, already diagnosed and in treatment (12,13).

The incidence of IRIS varies for different cohorts, being more commonly presented as tuberculosis, abscesses and folliculitis, varicella zoster virus infections, herpes simplex, cryptococcal

---

**TABLE 1. Biological evolution after diagnosis of HIV to death (W0-W16)**

<table>
<thead>
<tr>
<th>Test name</th>
<th>1 (W0)</th>
<th>2 (W2)</th>
<th>3 (W6)</th>
<th>4 (W12)</th>
<th>5 (W16)</th>
<th>Normal interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White blood cell count /mmc</td>
<td>1,650</td>
<td>2,100</td>
<td>5,600</td>
<td>3,100</td>
<td>4,700</td>
<td>4,000-9,000</td>
</tr>
<tr>
<td>Neutrophil /mmc</td>
<td>880</td>
<td>990</td>
<td>2,350</td>
<td>2,410</td>
<td>4,090</td>
<td>2,000-6,300</td>
</tr>
<tr>
<td>Lymphocyte /mmc</td>
<td>530</td>
<td>790</td>
<td>2790</td>
<td>550</td>
<td>440</td>
<td>1,000-3,600</td>
</tr>
<tr>
<td>LT-CD4</td>
<td>42</td>
<td>198</td>
<td>128</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin g/dl</td>
<td>7.6</td>
<td>9.9</td>
<td>8.5</td>
<td>8.9</td>
<td>9.1</td>
<td>12-14</td>
</tr>
<tr>
<td>MCV fl</td>
<td>87.9</td>
<td>92</td>
<td>104</td>
<td>102</td>
<td>104</td>
<td>80-100</td>
</tr>
<tr>
<td>MCH pg</td>
<td>30.4</td>
<td>29.9</td>
<td>25.8</td>
<td>33.9</td>
<td>26.3</td>
<td>24-33</td>
</tr>
<tr>
<td>Platelets /mmc</td>
<td>81,000</td>
<td>117,000</td>
<td>148,000</td>
<td>196,000</td>
<td>72,000</td>
<td>150,000-450,000</td>
</tr>
</tbody>
</table>

**Biochemical tests**

<table>
<thead>
<tr>
<th>Test name</th>
<th>1 (W0)</th>
<th>2 (W2)</th>
<th>3 (W6)</th>
<th>4 (W12)</th>
<th>5 (W16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin g/dl</td>
<td>2.6</td>
<td>3.15</td>
<td>3.04</td>
<td>2.91</td>
<td>2.63</td>
</tr>
<tr>
<td>Creatinine mg/dl</td>
<td>0.72</td>
<td>0.78</td>
<td>0.87</td>
<td>0.59</td>
<td>1.09</td>
</tr>
</tbody>
</table>

**Inflammatory markers**

<table>
<thead>
<tr>
<th>Test name</th>
<th>1 (W0)</th>
<th>2 (W2)</th>
<th>3 (W6)</th>
<th>4 (W12)</th>
<th>5 (W16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP mg/l</td>
<td>13</td>
<td>6.51</td>
<td>34.49</td>
<td>41.17</td>
<td>60.43</td>
</tr>
<tr>
<td>VSH mm/h</td>
<td>100</td>
<td>52</td>
<td>98</td>
<td>24</td>
<td>18</td>
</tr>
<tr>
<td>RNA-HIV c/ml</td>
<td>368,000</td>
<td>76</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Immunology**

<table>
<thead>
<tr>
<th>Test name</th>
<th>1 (W0)</th>
<th>2 (W2)</th>
<th>3 (W6)</th>
<th>4 (W12)</th>
<th>5 (W16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor markers tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEA ng/ml</td>
<td>0.79</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA125 U/ml</td>
<td>4.93</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA19.9 U/ml</td>
<td>2.73</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA15.3 U/ml</td>
<td>10.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Bone marrow examination**

- Slightly decreased erythrocyte series, with normoerythroblasts in all stages of maturation, polychromatophilic and oxyphilic erythroblasts predominate;
- Granulocyte series slightly decreased quantitatively, with slight inhibition in maturation, with normal morphology, blasts 2%
- Megakaryocyte series with the presence of groups of 10-15 and 15-20 platelets.

**Lymph node histology**

- Lymph node with preserved architecture showing pericapsular, subcapsular and medullary vascular proliferation with irregular contour lined with a single layer of flattened cells with soft appearance, without accentuated pleomorphism and without atypical mitotic figures, accompanied by a proliferation of fusiform cells, arranged in bundles intersected delimiting pseudovascular spaces containing erythrocytes. Frequent siderophagous. Paracortical hyperplasia with frequent plasma cells, large immunoblastic cells, histiocytes and small reactive lymphocytes.

**Lymph node immunohistochemistry**

- HHV8 is positive in vascular proliferation. ERG is positive in vascular proliferation. CD20 is positive in small reactive B lymphocytes. PAX5 is positive in small reactive B lymphocytes. CD3 is positive in frequent small reactive T lymphocytes. CD30 is positive in small / medium activated cells. CD15 is positive in small activated lymphocytes and granulocytes.

Conclusion: Kaposi sarcoma
TABLE 2. Particularities of the case

1. “Late presentation” HIV diagnostic was consequent to the delayed medical visit due to the fear of pandemic COVID-19, but also to the lower degree of suspicion of doctors for HIV infection to aging woman.
2. The suspicion of HIV infection was sustained by the hematologist, beginning with differential diagnosis of pancytopenia and the submandibular lymphadenopathy.
3. The diagnosis of SK was supported by the macroscopic aspect of the cutaneous-mucosal lesions, the anatomo-pathological and immunohistochemical examination, with the prove of HHV-8 involvement.
4. Severe immunosuppression at the time of diagnosis and initiation of ART therapy, based on the integrase inhibitor (Elvitegravir), were predictors of IRIS. The initiation of ART before oncology therapy for SK was decided because of delayed access to oncology services during the COVID-19 pandemic.
5. The inflammatory response immune system (IRIS) has been clinically expressed by enlarging KS lesions of the mucosa and soft tissues and visceral dissemination, while HIV-RNA viremia dropped and L-CD4 count increased. Following the nonresponding corticosteroid therapy and delay of oncological procedures, the patient died.

meningitis, molluscum contagiosum or Kaposi’s sarcoma, which contribute to increased mortality from these diseases (14,15).

The most common system for scoring the prognostic risk of KS belongs to the ACTG Oncology Committee (AIDS Clinical Trials Group), which considers the distribution of the tumor, the number of LCD4, the presence of opportunistic infections and the dependence scoring. Biomarkers with prognostic significance for survival prediction are L-CD4 number, LT-CD4 / LT-CD8 ratio, hematocrit, β2-microglobulin, neopterin (16,17).

The pathogenesis of SK in IRIS was explained by the dysfunction of the host inflammatory response, which involves the activation of HHV8 antigens (18). Decreased viral replication and increased LCD4 increase the release of inflammatory cytokines, which promote HHV8 gene expression, viral antigen production, and reversal of the Th2 (CD4) / Th1 (CD8) immune response, amplifying the production of inflammatory and LT-cytotoxic cytokines. Aberrant signals of excessive inflammation promote endothelial cell angiogenesis, contributing to the manifestations of KS (19).

Therapy of cutaneous forms of KS could be limited to highly active antiretroviral therapy. Other options for the treatment of symptomatic forms of KS are surgery by local excision, radiotherapy, cryotherapy, laser therapy or topical retinoids ointments. Chemotherapy is recommended for visceral, oral or lymph node involvement. First-line liposomal doxorubicin, or second-line paclitaxel regimens are recommended every two or three weeks. Pomalidomide, Gemcitabine, Lenalidomide Vinorelbine could be used following the failure on previous two therapeutic lines (16,17,18,20).

We summarized in table 2 the particularities of our case.

CONCLUSIONS

Pancytopenia could be an indication of acquired immunosuppression, irrespective of age and differential diagnosis requires systematic HIV testing recommendation by hematological protocols.

The extension of Kaposi’s sarcoma after initiating antiretroviral therapy in advanced HIV immunosuppression is a severe manifestation of the inflammatory syndrome of immune reconstruction, with potentially fatal evolution.

The difficulties of the multidisciplinary approach of the patient with HIV infection and opportunistic neoplastic disease, the delayed access to diagnostic services and onco-hematological therapy, are amplified in the pandemic context of COVID-19, proving the vulnerability of these people.

REFERENCES

8. Lima CT, Araújo PSR, Teixeira HM, Santos JBD, Silveira VMD. Clinical and laboratory characteristics, staging, and outcomes of individuals


